Whole Body Bone Scintigraphy in Tenofovir-related Osteomalacia: a Case Report

Overview

Journal J Med Case Rep

Publisher Biomed Central

Specialty General Medicine

Date 2009 Oct 16

PMID 19830218

Citations 8

Authors

Antonio Di Biagio

Raffaella Rosso

Patrizia Monteforte

Rodolfo Russo

Guido Rovetta

Claudio Viscoli

Affiliations

Soon will be listed here.

Abstract

Introduction: Tenofovir disoproxil fumarate (Viread((R))) is the only nucleotide reverse transcriptase inhibitor currently approved for the treatment of HIV. It is frequently prescribed not only for its efficacy but also for its decreased side effect profile compared with other nucleotide analogs. In addition, it is now increasingly recognized as a cause of acquired Fanconi's syndrome in individuals with HIV.

Case Presentation: We describe a 48-year-old woman infected with HIV, with chronic renal insufficiency, who developed Fanconi's syndrome after inclusion of tenofovir disoproxil fumarate in her antiretroviral therapy. A whole body bone scintigraphy was performed, revealing an abnormal distribution of radiotracer uptake, with characteristic changes compatible with osteomalacia. All symptoms disappeared after tenofovir discontinuation and mineral supplementation. No other explanation for the sudden and complete resolution of the bone disease was found.

Conclusion: The case highlights the role of whole body bone scintigraphy in the diagnosis of tenofovir-related osteomalacia.

Citing Articles

Subtrochanteric Pathological Femur Fracture in an HIV-Positive Patient on Tenofovir-based antiretroviral therapy: A Case Report and Review of the Literature.

Choudhary S, Rangasamy K, Naidu S, Sachdeva R, Sharma A J Orthop Case Rep. 2023; 13(2):14-20.

PMID: 37144071 PMC: 10152932. DOI: 10.13107/jocr.2023.v13.i02.3538.

Bone health and HIV in resource-limited settings: a scoping review.

Matovu F, Wattanachanya L, Beksinska M, Pettifor J, Ruxrungtham K Curr Opin HIV AIDS. 2016; 11(3):306-25.

PMID: 27023284 PMC: 5578733. DOI: 10.1097/COH.0000000000000274.

Hypophosphatemic osteomalacia induced by tenofovir in HIV-infected patients.

Mateo L, Holgado S, Marinoso M, Perez-Andres R, Bonjoch A, Romeu J Clin Rheumatol. 2014; 35(5):1271-9.

PMID: 24794489 DOI: 10.1007/s10067-014-2627-x.

Tenofovir effect on the kidneys of HIV-infected patients: a double-edged sword?.

Tourret J, Deray G, Isnard-Bagnis C J Am Soc Nephrol. 2013; 24(10):1519-27.

PMID: 24052632 PMC: 3785270. DOI: 10.1681/ASN.2012080857.

Hypophosphatemic Osteomalacia Associated with Tenofovir: a Multidisciplinary Approach is Required.

De Socio G, Fabbriciani G, Massarotti M, Messina S, Cecchini E, Marasini B Mediterr J Hematol Infect Dis. 2012; 4(1):e2012025.

PMID: 22708040 PMC: 3375688. DOI: 10.4084/MJHID.2012.025.

References

Verhelst D, Monge M, Meynard J, Fouqueray B, Mougenot B, Girard P . Fanconi syndrome and renal failure induced by tenofovir: a first case report. Am J Kidney Dis. 2002; 40(6):1331-3. DOI: 10.1053/ajkd.2002.36924. View

Schaaf B, Aries S, Kramme E, Steinhoff J, Dalhoff K . Acute renal failure associated with tenofovir treatment in a patient with acquired immunodeficiency syndrome. Clin Infect Dis. 2003; 37(3):e41-3. DOI: 10.1086/376643. View

Parsonage M, Wilkins E, Snowden N, Issa B, Savage M . The development of hypophosphataemic osteomalacia with myopathy in two patients with HIV infection receiving tenofovir therapy. HIV Med. 2005; 6(5):341-6. DOI: 10.1111/j.1468-1293.2005.00318.x. View

Montessori V, Press N, Harris M, Akagi L, Montaner J . Adverse effects of antiretroviral therapy for HIV infection. CMAJ. 2004; 170(2):229-38. PMC: 315530. View

Schooley R, Ruane P, Myers R, Beall G, Lampiris H, Berger D . Tenofovir DF in antiretroviral-experienced patients: results from a 48-week, randomized, double-blind study. AIDS. 2002; 16(9):1257-63. DOI: 10.1097/00002030-200206140-00008. View